Plasma Concentrations and Safety of Lopinavir/Ritonavir in COVID-19 Patients-Reference-Cited by-同舟云学术

Plasma Concentrations and Safety of Lopinavir/Ritonavir in COVID-19 Patients

Published:2021-02 Issue:1 Volume:43 Page:131-135
ISSN:0163-4356
Container-title:Therapeutic Drug Monitoring
language:en
Short-container-title:

Author:

Chouchana Laurent,Boujaafar Sana,Gana Ines,Preta Laure-Hélène,Regard Lucile,Legendre Paul,Azoulay Celia,Canouï Etienne,Zerbit Jeremie,Carlier Nicolas,Terrier Benjamin,Kernéis Solen,Batista Rui,Treluyer Jean-Marc,Zheng Yi,Benaboud Sihem

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Pharmacology

Reference17 articles.

1. Potential therapeutic agents against COVID-19: what we know so far;Lu;J Chin Med Assoc.,2020

2. Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysis;Kanters;Lancet HIV,2017

3. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings;Chu;Thorax,2004

4. Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for middle east respiratory syndrome;Kim;Antivir Ther.,2016

5. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro;Choy;Antivir Res.,2020

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhanced Solubility and Dissolution of Drug-drug Cocrystals of Lopinavir-Ritonavir;Indian Journal of Pharmaceutical Education and Research;2023-06-05

2. Detection of Adverse Drug Reactions in COVID-19 Hospitalized Patients in Saudi Arabia: A Retrospective Study by ADR Prompt Indicators;Healthcare;2023-02-23

3. Safety profile of the lopinavir/ritonavir combination before and during the SARS-CoV-2 pandemic;Therapies;2022-10

4. Lopinavir-menthol co-crystals for enhanced dissolution rate and intestinal absorption;Journal of Drug Delivery Science and Technology;2022-08

5. A systematic review of real-world clinical practice data in COVID-19: non-interventional studies;FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology;2022-04-15